Member Info for inanaco

ImmmunoBody® plasmid coated onto gold particles using a gene gun.

for SCIB2

as Debenhams Board stated

the board remains open to constructive suggestions from shareholders that are in the interests of the business as a whole.”

Aimbig ... do you want to Invest ?

anyway i will leave you Pontificating to your audience ATB

i am sure that you will have the command of 51% of scancell by Monday .. good luck ..

so it continues

anyway i will leave you Pontificating to your audience ATB

i am sure that you will have the command of 51% of scancell by Monday .. good luck ..

You bluster your way to make yourself important ...

that is all ...

Public Limited Company and the Private Limited Company raise their capital through shares. However, the difference is that the PLC can quote the shares in a stock exchange whereas the Ltd Company cannot

explain the difference ?

Don't really care .. Aimbig ..

nothing in your posts would indicate your leadership qualifications .. however if you are a past director of Carillion PLC then i apologise ..

The funds raised at the end of the previous financial year and the beginning of this period have enabled Scancell to move towards obtaining regulatory approvals for the initiation of the SCIB1 checkpoint inhibitor combination Phase 2 study in the US and UK, in addition to funding the continuing development of our Moditope® products, Modi-1 and Modi-2, and the underlying platform technology.

Patents awarded with respect to the Moditope® platform and our on-going collaborations mean that we are now well positioned to develop Moditope® based therapeutics, such as vaccines and adoptive T-cell therapies, with the potential to address the unmet need across a broad range of hard to treat cancers.

The Company's recent senior management appointments of Samantha Paston as Head of Research and Adrian Parry as Head of Manufacturing provide additional expertise to enable the transition of our products from the laboratory to the clinic.

Scancell's focus for the immediate future is to initiate the planned Phase 2 clinical study for our lead ImmunoBody®, SCIB1, and to advance our lead Moditope® vaccine, Modi-1, towards the clinic. A positive outcome from both or either of these studies should represent significant value to shareholders.

John Chiplin

Chairman

you are wasting your time ... the BOD are not interested in a Union of shareholders that can muster up 1/4 % between them, you will get the Standard RNS reply

as per RNS ... the plan has not changed

will not influence Scancell at all . indeed most of you ranting on subjects you don't have a clue about just highlights why Aimbig is not a Director
and Those of us who are (not scancell) ... just watch this fiasco on here with amusement
even Mike Ashley holding 30% of Debenhams cant stamp his feet it took 56% of shareholders to change Director

""A total of 56% of shares voted were against both directors after a number of shareholders either withheld or failed to use their votes."""

basically you are wasting your time posting ... unless you are trying to weaken the Shaprice for your own advantage

hits you like a sledge hammer Nom ....

Our study has several limitations. First, our approach is designed to detect biophysicochemical motifs in TCRs with specificity for shared antigens.

It cannot identify TCRs with specificity for patient-specific tumor neoantigens

you keep wishing to drag me into discussing things of no consequence

scancell already has High Value delivery systems for its vaccines .. anything else developed via any other source as Crumbs has discovered only adds to the potential.. in other words what has been achieved demonstrates it does deliver the type of T cells that can infiltrate cancer ...

the question than as your link highlights is antigens ...

scancell has plenty ... thank you PS ... patented

Ruckrover PLC ....

buyer of Val ..

fund manager BIG experience https://woodfordfunds.com/funds/wpct/

http://www.lse.co.uk/ShareChart.asp?sharechart=WPCT&share=woodford

Ruckrovers and Tommy Model ..

LOL

ruckrover ...

you are not big pharma .. or a buyer capable of buying scancell ..

and your post contains nothing that is going to help you value scancell future

just saying unless your model understands reality ...

ie PD-1 current sales .... which include a 70% failure rate ... which is our market .. then you will never get the basic information near to make an informed output

snap

in that algo

is efficacy so you can base it on 55% as per scancells estimates

but change it instantly with fact ... up or down

SCIB1 mark 2 is worth another £3